Recent Advances in Immune Cell Therapy for Glioblastoma.

Abstract

Glioblastoma (GBM) is the most malignant form of astrocytoma with short survival and a high recurrence rate and remains a global problem. Currently, surgery, chemotherapy, radiotherapy, and other comprehensive treatments are the main treatment modalities, but patients still have a poor prognosis mainly due to the infiltrative growth of GBM and the protective effect of the blood-brain barrier on tumor cells. Therefore, immunotherapy is expected to be a good option for GBM. In the immune system, different cells play varying roles in the treatment of GBM, so understanding the roles played by various immune cells in treating GBM and considering how to combine these effects to maximize the efficacy of these cells is important for the selection of comprehensive and optimal treatment plans and improving GBM prognosis. Therefore, this study reviews the latest research progress on the role of various types of immune cells in the treatment of GBM.

• Authors: Xianhui Kang, Yiyang Zheng, Wandong Hong, Xixi Chen, Huiting Li, Baojun Huang, Zhenyang Huang, Hongli Tang, Wujun Geng
• Journal: Frontiers in immunology (Front Immunol) Vol. 11 Pg. 544563 ( 2020) ISSN: 1664-3224 [Electronic] Switzerland
• PMID: 33193310 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020 Kang, Zheng, Hong, Chen, Li, Huang, Huang, Tang and Geng.

Topics

• Blood-Brain Barrier (immunology)
• Brain Neoplasms (immunology, pathology, therapy)
• Glioblastoma (immunology, mortality, therapy)
• Humans
• Immunotherapy, Adoptive